Demethylation at gene promoters induced by DNMTis can result in several beneficial anti-tumor effects: 1) re-expression of tumor suppressor genes, 2) reversal of chemotherapy resistance due to de-repression of SMAD1 and 3) upregulation of the Ag presentation machinery and IFN response genes, which can increase immune sensitivity, thus offering potential for combination with immunotherapy (Almstedt et al., 2010; Chiappinelli et al., 2015). This evidence concerns the gene SMAD1 and neoplasm.